51
|
Amani N, Dorkoosh FA, Mobedi H. ADCs, as Novel Revolutionary Weapons for Providing a Step Forward in Targeted Therapy of Malignancies. Curr Drug Deliv 2020; 17:23-51. [DOI: 10.2174/1567201816666191121145109] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2019] [Revised: 08/01/2019] [Accepted: 10/29/2019] [Indexed: 11/22/2022]
Abstract
:Antibody drug conjugates (ADCs), as potent pharmaceutical trojan horses for cancer treatment, provide superior efficacy and specific targeting along with low risk of adverse reactions compared to traditional chemotherapeutics. In fact, the development of these agents combines the selective targeting capability of monoclonal antibody (mAb) with high cytotoxicity of chemotherapeutics for controlling the neoplastic mass growth. Different ADCs (more than 60 ADCs) in preclinical and clinical trials were introduced in this novel pharmaceutical field. Various design-based factors must be taken into account for improving the functionality of ADC technology, including selection of appropriate target antigen and high binding affinity of fragment (miniaturized ADCs) or full mAbs (preferentially use of humanized or fully human antibodies compared to murine and chimeric ones), use of bispecific antibodies for dual targeting effect, linker engineering and conjugation method efficacy to obtain more controlled drug to antibody ratio (DAR). Challenging issues affecting therapeutic efficacy and safety of ADCs, including bystander effect, on- and off-target toxicities, multi drug resistance (MDR) are also addressed. 4 FDA-approved ADCs in the market, including ADCETRIS ®, MYLOTARG®, BESPONSA ®, KADCYLA®. The goal of the current review is to evaluate the key parameters affecting ADCs development.
Collapse
Affiliation(s)
- Nooshafarin Amani
- Department of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
| | - Farid Abedin Dorkoosh
- Medical Biomaterial Research Center (MBRC), Tehran University of Medical Sciences, Tehran, Iran
| | - Hamid Mobedi
- Novel Drug Delivery Systems (NDDS) Department, Iran Polymer and Petrochemical Institute, Tehran, Iran
| |
Collapse
|
52
|
Antibody Conjugates-Recent Advances and Future Innovations. Antibodies (Basel) 2020; 9:antib9010002. [PMID: 31936270 PMCID: PMC7148502 DOI: 10.3390/antib9010002] [Citation(s) in RCA: 60] [Impact Index Per Article: 15.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2019] [Revised: 12/20/2019] [Accepted: 12/21/2019] [Indexed: 12/18/2022] Open
Abstract
Monoclonal antibodies have evolved from research tools to powerful therapeutics in the past 30 years. Clinical success rates of antibodies have exceeded expectations, resulting in heavy investment in biologics discovery and development in addition to traditional small molecules across the industry. However, protein therapeutics cannot drug targets intracellularly and are limited to soluble and cell-surface antigens. Tremendous strides have been made in antibody discovery, protein engineering, formulation, and delivery devices. These advances continue to push the boundaries of biologics to enable antibody conjugates to take advantage of the target specificity and long half-life from an antibody, while delivering highly potent small molecule drugs. While the "magic bullet" concept produced the first wave of antibody conjugates, these entities were met with limited clinical success. This review summarizes the advances and challenges in the field to date with emphasis on antibody conjugation, linker-payload chemistry, novel payload classes, absorption, distribution, metabolism, and excretion (ADME), and product developability. We discuss lessons learned in the development of oncology antibody conjugates and look towards future innovations enabling other therapeutic indications.
Collapse
|
53
|
Abstract
The prototypical ADC mechanism involving antigen-mediated uptake and lysosomal release is both elegantly simple and scientifically compelling. However, recent clinical-stage failures have prompted a reevaluation of this delivery paradigm and have resulted in an array of new technologies that have the potential to improve the safety and efficacy of up and coming programs. These innovations can generally be categorized into seven areas that will be elaborated on in this chapter: (1) Exploiting new payload mechanisms; (2) Increasing the drug-antibody ratio (DAR); (3) Increasing the antibody penetration; (4) Overcoming ADC resistance mechanisms; (5) Increasing the efficiency of ADC uptake and processing; (6) Mitigating off-target payload exposure; and (7) Employment of noncytotoxic payloads. It is our belief that these seven areas capture the current "landscape" of innovations that are taking place in the design of next-generation ADCs. Together, these advancements are reshaping the ADC field and providing a path forward in the face of the recent clinical setbacks.
Collapse
Affiliation(s)
- L Nathan Tumey
- Department of Pharmacy and Pharmaceutical Sciences, Binghamton University, Binghamton, NY, USA.
- Pfizer Inc., Groton, CT, USA.
| |
Collapse
|
54
|
Dragovich PS, Adhikari P, Blake RA, Blaquiere N, Chen J, Cheng YX, den Besten W, Han J, Hartman SJ, He J, He M, Rei Ingalla E, Kamath AV, Kleinheinz T, Lai T, Leipold DD, Li CS, Liu Q, Lu J, Lu Y, Meng F, Meng L, Ng C, Peng K, Lewis Phillips G, Pillow TH, Rowntree RK, Sadowsky JD, Sampath D, Staben L, Staben ST, Wai J, Wan K, Wang X, Wei B, Wertz IE, Xin J, Xu K, Yao H, Zang R, Zhang D, Zhou H, Zhao Y. Antibody-mediated delivery of chimeric protein degraders which target estrogen receptor alpha (ERα). Bioorg Med Chem Lett 2019; 30:126907. [PMID: 31902710 DOI: 10.1016/j.bmcl.2019.126907] [Citation(s) in RCA: 75] [Impact Index Per Article: 15.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2019] [Revised: 12/09/2019] [Accepted: 12/10/2019] [Indexed: 12/31/2022]
Abstract
Chimeric molecules which effect intracellular degradation of target proteins via E3 ligase-mediated ubiquitination (e.g., PROTACs) are currently of high interest in medicinal chemistry. However, these entities are relatively large compounds that often possess molecular characteristics which may compromise oral bioavailability, solubility, and/or in vivo pharmacokinetic properties. Accordingly, we explored whether conjugation of chimeric degraders to monoclonal antibodies using technologies originally developed for cytotoxic payloads might provide alternate delivery options for these novel agents. In this report we describe the construction of several degrader-antibody conjugates comprised of two distinct ERα-targeting degrader entities and three independent ADC linker modalities. We subsequently demonstrate the antigen-dependent delivery to MCF7-neo/HER2 cells of the degrader payloads that are incorporated into these conjugates. We also provide evidence for efficient intracellular degrader release from one of the employed linkers. In addition, preliminary data are described which suggest that reasonably favorable in vivo stability properties are associated with the linkers utilized to construct the degrader conjugates.
Collapse
Affiliation(s)
| | - Pragya Adhikari
- Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA
| | - Robert A Blake
- Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA
| | | | - Jinhua Chen
- WuXi AppTec, Waigaoqiao Free Trade Zone, 288 Fute Zhong Road, Shanghai 200131, China
| | - Yun-Xing Cheng
- Pharmaron Beijing, Co. Ltd., BDA Beijing, 6 Tai He Road, 100176, China
| | | | - Jinping Han
- Pharmaron Beijing, Co. Ltd., BDA Beijing, 6 Tai He Road, 100176, China
| | | | - Jintang He
- Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA
| | - Mingtao He
- Pharmaron Beijing, Co. Ltd., BDA Beijing, 6 Tai He Road, 100176, China
| | | | - Amrita V Kamath
- Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA
| | | | - Tommy Lai
- WuXi AppTec, Waigaoqiao Free Trade Zone, 288 Fute Zhong Road, Shanghai 200131, China
| | | | - Chun Sing Li
- WuXi AppTec, Waigaoqiao Free Trade Zone, 288 Fute Zhong Road, Shanghai 200131, China
| | - Qi Liu
- Pharmaron Beijing, Co. Ltd., BDA Beijing, 6 Tai He Road, 100176, China
| | - Jiawei Lu
- WuXi Biologics, Waigaoqiao Free Trade Zone, 288 Fute Zhong Road, Shanghai 200131, China
| | - Ying Lu
- WuXi AppTec, Waigaoqiao Free Trade Zone, 288 Fute Zhong Road, Shanghai 200131, China
| | - Fanwei Meng
- Pharmaron Beijing, Co. Ltd., BDA Beijing, 6 Tai He Road, 100176, China
| | - Lingyao Meng
- Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA
| | - Carl Ng
- Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA
| | - Kaishan Peng
- WuXi Biologics, Waigaoqiao Free Trade Zone, 288 Fute Zhong Road, Shanghai 200131, China
| | | | - Thomas H Pillow
- Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA
| | | | - Jack D Sadowsky
- Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA
| | - Deepak Sampath
- Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA
| | - Leanna Staben
- Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA
| | - Steven T Staben
- Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA
| | - John Wai
- WuXi AppTec, Waigaoqiao Free Trade Zone, 288 Fute Zhong Road, Shanghai 200131, China
| | - Kunpeng Wan
- WuXi AppTec, Waigaoqiao Free Trade Zone, 288 Fute Zhong Road, Shanghai 200131, China
| | - Xinxin Wang
- WuXi AppTec, Waigaoqiao Free Trade Zone, 288 Fute Zhong Road, Shanghai 200131, China
| | - BinQing Wei
- Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA
| | - Ingrid E Wertz
- Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA
| | - Jianfeng Xin
- Pharmaron Beijing, Co. Ltd., BDA Beijing, 6 Tai He Road, 100176, China
| | - Keyang Xu
- Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA
| | - Hui Yao
- WuXi AppTec, Waigaoqiao Free Trade Zone, 288 Fute Zhong Road, Shanghai 200131, China
| | - Richard Zang
- Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA
| | - Donglu Zhang
- Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA
| | - Hao Zhou
- WuXi AppTec, Waigaoqiao Free Trade Zone, 288 Fute Zhong Road, Shanghai 200131, China
| | - Yongxin Zhao
- WuXi AppTec, Waigaoqiao Free Trade Zone, 288 Fute Zhong Road, Shanghai 200131, China
| |
Collapse
|
55
|
Karpov AS, Nieto-Oberhuber CM, Abrams T, Beng-Louka E, Blanco E, Chamoin S, Chene P, Dacquignies I, Daniel D, Dillon MP, Doumampouom-Metoul L, Drosos N, Fedoseev P, Furegati M, Granda B, Grotzfeld RM, Hess Clark S, Joly E, Jones D, Lacaud-Baumlin M, Lagasse-Guerro S, Lorenzana EG, Mallet W, Martyniuk P, Marzinzik AL, Mesrouze Y, Nocito S, Oei Y, Perruccio F, Piizzi G, Richard E, Rudewicz PJ, Schindler P, Velay M, Venstrom K, Wang P, Zurini M, Lafrance M. Discovery of Potent and Selective Antibody-Drug Conjugates with Eg5 Inhibitors through Linker and Payload Optimization. ACS Med Chem Lett 2019; 10:1674-1679. [PMID: 31857845 DOI: 10.1021/acsmedchemlett.9b00468] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2019] [Accepted: 12/03/2019] [Indexed: 12/16/2022] Open
Abstract
Targeted antimitotic agents are a promising class of anticancer therapies. Herein, we describe the development of a potent and selective antimitotic Eg5 inhibitor based antibody-drug conjugate (ADC). Preliminary studies were performed using proprietary Eg5 inhibitors which were conjugated onto a HER2-targeting antibody using maleimido caproyl valine-citrulline para-amino benzocarbamate, or MC-VC-PABC cleavable linker. However, the resulting ADCs lacked antigen-specificity in vivo, probably from premature release of the payload. Second-generation ADCs were then developed, using noncleavable linkers, and the resulting conjugates (ADC-4 and ADC-10) led to in vivo efficacy in an HER-2 expressing (SK-OV-3ip) mouse xenograft model while ADC-11 led to in vivo efficacy in an anti-c-KIT (NCI-H526) mouse xenograft model in a target-dependent manner.
Collapse
Affiliation(s)
- Alexei S. Karpov
- Novartis Institutes for BioMedical Research, Fabrikstrasse 2, CH-4056 Basel, Switzerland
| | | | - Tinya Abrams
- Novartis Institutes for BioMedical Research, 181 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States
| | - Edwige Beng-Louka
- Novartis Institutes for BioMedical Research, Fabrikstrasse 2, CH-4056 Basel, Switzerland
| | - Enrique Blanco
- Novartis Institutes for BioMedical Research, Fabrikstrasse 2, CH-4056 Basel, Switzerland
| | - Sylvie Chamoin
- Novartis Institutes for BioMedical Research, Fabrikstrasse 2, CH-4056 Basel, Switzerland
| | - Patrick Chene
- Novartis Institutes for BioMedical Research, Fabrikstrasse 2, CH-4056 Basel, Switzerland
| | - Isabelle Dacquignies
- Novartis Institutes for BioMedical Research, Fabrikstrasse 2, CH-4056 Basel, Switzerland
| | - Dylan Daniel
- Novartis Institutes for BioMedical Research, 5300 Chiron Way, Emeryville, California 94608, United States
| | - Michael P. Dillon
- Novartis Institutes for BioMedical Research, 181 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States
| | | | | | - Pavel Fedoseev
- Novartis Institutes for BioMedical Research, Fabrikstrasse 2, CH-4056 Basel, Switzerland
| | - Markus Furegati
- Novartis Institutes for BioMedical Research, Fabrikstrasse 2, CH-4056 Basel, Switzerland
| | - Brian Granda
- Novartis Institutes for BioMedical Research, 181 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States
| | - Robert M. Grotzfeld
- Novartis Institutes for BioMedical Research, Fabrikstrasse 2, CH-4056 Basel, Switzerland
| | - Suzanna Hess Clark
- Novartis Institutes for BioMedical Research, 181 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States
| | - Emilie Joly
- Novartis Institutes for BioMedical Research, Fabrikstrasse 2, CH-4056 Basel, Switzerland
| | - Darryl Jones
- Novartis Institutes for BioMedical Research, Fabrikstrasse 2, CH-4056 Basel, Switzerland
| | - Marion Lacaud-Baumlin
- Novartis Institutes for BioMedical Research, Fabrikstrasse 2, CH-4056 Basel, Switzerland
| | | | - Edward G. Lorenzana
- Novartis Institutes for BioMedical Research, 5300 Chiron Way, Emeryville, California 94608, United States
| | - William Mallet
- Novartis Institutes for BioMedical Research, 5300 Chiron Way, Emeryville, California 94608, United States
| | - Piotr Martyniuk
- Novartis Institutes for BioMedical Research, Fabrikstrasse 2, CH-4056 Basel, Switzerland
| | - Andreas L. Marzinzik
- Novartis Institutes for BioMedical Research, Fabrikstrasse 2, CH-4056 Basel, Switzerland
| | - Yannick Mesrouze
- Novartis Institutes for BioMedical Research, Fabrikstrasse 2, CH-4056 Basel, Switzerland
| | - Sandro Nocito
- Novartis Institutes for BioMedical Research, Fabrikstrasse 2, CH-4056 Basel, Switzerland
| | - Yoko Oei
- Novartis Institutes for BioMedical Research, 5300 Chiron Way, Emeryville, California 94608, United States
| | - Francesca Perruccio
- Novartis Institutes for BioMedical Research, Fabrikstrasse 2, CH-4056 Basel, Switzerland
| | - Grazia Piizzi
- Novartis Institutes for BioMedical Research, Fabrikstrasse 2, CH-4056 Basel, Switzerland
| | - Etienne Richard
- Novartis Institutes for BioMedical Research, Fabrikstrasse 2, CH-4056 Basel, Switzerland
| | - Patrick J. Rudewicz
- Novartis Institutes for BioMedical Research, 5300 Chiron Way, Emeryville, California 94608, United States
| | - Patrick Schindler
- Novartis Institutes for BioMedical Research, Fabrikstrasse 2, CH-4056 Basel, Switzerland
| | - Mélanie Velay
- Novartis Institutes for BioMedical Research, Fabrikstrasse 2, CH-4056 Basel, Switzerland
| | - Kristine Venstrom
- Novartis Institutes for BioMedical Research, 5300 Chiron Way, Emeryville, California 94608, United States
| | - Peiyin Wang
- Novartis Institutes for BioMedical Research, 5300 Chiron Way, Emeryville, California 94608, United States
| | - Mauro Zurini
- Novartis Institutes for BioMedical Research, Fabrikstrasse 2, CH-4056 Basel, Switzerland
| | - Marc Lafrance
- Novartis Institutes for BioMedical Research, Fabrikstrasse 2, CH-4056 Basel, Switzerland
- Novartis Institutes for BioMedical Research, 181 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States
| |
Collapse
|
56
|
Khongorzul P, Ling CJ, Khan FU, Ihsan AU, Zhang J. Antibody–Drug Conjugates: A Comprehensive Review. Mol Cancer Res 2019; 18:3-19. [DOI: 10.1158/1541-7786.mcr-19-0582] [Citation(s) in RCA: 248] [Impact Index Per Article: 49.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2019] [Revised: 08/22/2019] [Accepted: 10/22/2019] [Indexed: 11/16/2022]
|
57
|
Tag and release: strategies for the intracellular cleavage of protein conjugates. Curr Opin Chem Biol 2019; 52:39-46. [DOI: 10.1016/j.cbpa.2019.04.019] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2019] [Revised: 04/15/2019] [Accepted: 04/18/2019] [Indexed: 01/12/2023]
|
58
|
Zang C, Wang H, Li T, Zhang Y, Li J, Shang M, Du J, Xi Z, Zhou C. A light-responsive, self-immolative linker for controlled drug delivery via peptide- and protein-drug conjugates. Chem Sci 2019; 10:8973-8980. [PMID: 31762977 PMCID: PMC6857671 DOI: 10.1039/c9sc03016f] [Citation(s) in RCA: 28] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2019] [Accepted: 08/08/2019] [Indexed: 01/01/2023] Open
Abstract
Photoirradiation of the PC4AP linker generates an active intermediate that reacts intramolecularly with a primary amine on the carrier peptide/protein, leading to rapid release of the drug without generating any toxic side products.
When designing prodrugs, choosing an appropriate linker is the key to achieving efficient, controlled drug delivery. Herein, we report the use of a photocaged C4′-oxidized abasic site (PC4AP) as a light-responsive, self-immolative linker. Any amine- or hydroxyl-bearing drug can be loaded onto the linker via a carbamate or carbonate bond, and the linker is then conjugated to a carrier peptide or protein via an alkyl chain. The PC4AP linker is stable under physiologically relevant conditions. However, photodecaging of the linker generates an active intermediate that reacts intramolecularly with a primary amine (the ε-amine of a lysine residue and the N-terminal amine) on the carrier, leading to rapid and efficient release of the drug via an addition–elimination cascade, without generating any toxic side products. We demonstrated that the use of this self-immolative linker to conjugate the anticancer drug doxorubicin to a cell-penetrating peptide or an antibody enabled targeted, controlled delivery of the drug to cells. Our results suggest that the linker can be used with a broad range of carriers, such as cell-penetrating peptides, proteins, antibodies, and amine-functionalized polymers, and thus will find a wide range of practical applications.
Collapse
Affiliation(s)
- Chuanlong Zang
- State Key Laboratory of Elemento-Organic Chemistry , Department of Chemical Biology , College of Chemistry , Nankai University , Tianjin 300071 , China .
| | - Huawei Wang
- State Key Laboratory of Elemento-Organic Chemistry , Department of Chemical Biology , College of Chemistry , Nankai University , Tianjin 300071 , China .
| | - Tiantian Li
- School of Pharmaceutical Sciences , Tsinghua University , 30 Shuangqing Rd. , Beijing 100084 , China
| | - Yingqian Zhang
- State Key Laboratory of Elemento-Organic Chemistry , Department of Chemical Biology , College of Chemistry , Nankai University , Tianjin 300071 , China .
| | - Jiahui Li
- State Key Laboratory of Elemento-Organic Chemistry , Department of Chemical Biology , College of Chemistry , Nankai University , Tianjin 300071 , China .
| | - Mengdi Shang
- State Key Laboratory of Elemento-Organic Chemistry , Department of Chemical Biology , College of Chemistry , Nankai University , Tianjin 300071 , China .
| | - Juanjuan Du
- School of Pharmaceutical Sciences , Tsinghua University , 30 Shuangqing Rd. , Beijing 100084 , China
| | - Zhen Xi
- State Key Laboratory of Elemento-Organic Chemistry , Department of Chemical Biology , College of Chemistry , Nankai University , Tianjin 300071 , China .
| | - Chuanzheng Zhou
- State Key Laboratory of Elemento-Organic Chemistry , Department of Chemical Biology , College of Chemistry , Nankai University , Tianjin 300071 , China .
| |
Collapse
|
59
|
Mahalingaiah PK, Ciurlionis R, Durbin KR, Yeager RL, Philip BK, Bawa B, Mantena SR, Enright BP, Liguori MJ, Van Vleet TR. Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates. Pharmacol Ther 2019; 200:110-125. [DOI: 10.1016/j.pharmthera.2019.04.008] [Citation(s) in RCA: 44] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2019] [Accepted: 04/19/2019] [Indexed: 12/13/2022]
|
60
|
Petersen J, Strømgaard K, Frølund B, Clemmensen C. Designing Poly-agonists for Treatment of Metabolic Diseases: Challenges and Opportunities. Drugs 2019; 79:1187-1197. [DOI: 10.1007/s40265-019-01153-6] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
|
61
|
Jang JH, Han SJ, Kim JY, Kim KI, Lee KC, Kang CS. Synthesis and Feasibility Evaluation of a new Trastuzumab Conjugate Integrated with Paclitaxel and 89Zr for Theranostic Application Against HER2-Expressing Breast Cancers. ChemistryOpen 2019; 8:451-456. [PMID: 31008009 PMCID: PMC6454217 DOI: 10.1002/open.201900037] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2019] [Revised: 03/12/2019] [Indexed: 01/26/2023] Open
Abstract
The preparation and in vitro evaluation of a theranostic conjugate composed of trastuzumab, paclitaxel (PTX), and deferoxamine (DFO)-chelated 89Zr have been reported. These comounds have potential applications against HER2 receptor positive breast cancers. We conjugated DFO and PTX to trastuzumab by exploiting simple conjugation chemistry. The conjugate (DFO-trastuzumab-PTX) showed excellent radiolabeling efficiency with 89Zr and the labeled conjugate had high in vitro stability in human serum. Furthermore, DFO-trastuzumab-PTX displayed comparable cytotoxicity with PTX and 89Zr-DFO-trastuzumab-PTX exhibited HER2 receptor-mediated binding on HER2-positive MDA-MB-231 breast cancer cells. The results of our in vitro study indicate high potential of 89Zr-DFO-trastuzumab-PTX to be utilized in the theranostic application against HER2-postive breast cancers.
Collapse
Affiliation(s)
- Joo Hee Jang
- Division of Applied RIKorea Institute of Radiological and Medical Sciences75 Nowon-ro, Nowon-guSeoulKorea01812
| | - Sang Jin Han
- Division of Applied RIKorea Institute of Radiological and Medical Sciences75 Nowon-ro, Nowon-guSeoulKorea01812
| | - Jung Young Kim
- Division of Applied RIKorea Institute of Radiological and Medical Sciences75 Nowon-ro, Nowon-guSeoulKorea01812
| | - Kwang Il Kim
- Division of Applied RIKorea Institute of Radiological and Medical Sciences75 Nowon-ro, Nowon-guSeoulKorea01812
| | - Kyo Chul Lee
- Division of Applied RIKorea Institute of Radiological and Medical Sciences75 Nowon-ro, Nowon-guSeoulKorea01812
| | - Chi Soo Kang
- Division of Applied RIKorea Institute of Radiological and Medical Sciences75 Nowon-ro, Nowon-guSeoulKorea01812
| |
Collapse
|
62
|
Wissler HL, Ehlerding EB, Lyu Z, Zhao Y, Zhang S, Eshraghi A, Buuh ZY, McGuth JC, Guan Y, Engle JW, Bartlett SJ, Voelz VA, Cai W, Wang RE. Site-Specific Immuno-PET Tracer to Image PD-L1. Mol Pharm 2019; 16:2028-2036. [PMID: 30875232 DOI: 10.1021/acs.molpharmaceut.9b00010] [Citation(s) in RCA: 38] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
The rapid ascension of immune checkpoint blockade treatments has placed an emphasis on the need for viable, robust, and noninvasive imaging methods for immune checkpoint proteins, which could be of diagnostic value. Immunoconjugate-based positron emission tomography (immuno-PET) allows for sensitive and quantitative imaging of target levels and has promising potential for the noninvasive evaluation of immune checkpoint proteins. However, the advancement of immuno-PET is currently limited by available imaging tools, which heavily rely on full-length IgGs with Fc-mediated effects and are heterogeneous mixtures upon random conjugation with chelators for imaging. Herein, we have developed a site-specific αPD-L1 Fab conjugate with the chelator 1,4,7-triazacyclononane- N, N', N″-triacetic acid (NOTA), enabling radiolabeling for PET imaging, using the amber suppression-mediated genetic incorporation of unnatural amino acid (UAA), p-azidophenylalanine. This Fab conjugate is homogeneous and demonstrated tight binding toward the PD-L1 antigen in vitro. The radiolabeled version, 64Cu-NOTA-αPD-L1, has been employed in PET imaging to allow for effective visualization and mapping of the biodistribution of PD-L1 in two normal mouse models, including the capturing of different PD-L1 expression levels in the spleens of the different mouse types. Follow-up in vivo blocking studies and ex vivo fluorescent staining further validated specific tissue uptakes of the imaging agent. This approach illustrates the utility of UAA-based site-specific Fab conjugation as a general strategy for making sensitive PET imaging probes, which could facilitate the elucidation of the roles of a wide variety of immune checkpoint proteins in immunotherapy.
Collapse
Affiliation(s)
- Haley L Wissler
- Department of Chemistry , Temple University , 1901 N. 13th Street , Philadelphia , Pennsylvania 19122 , United States
| | - Emily B Ehlerding
- Departments of Radiology and Medical Physics , University of Wisconsin-Madison , Madison , Wisconsin 53705 , United States
| | - Zhigang Lyu
- Department of Chemistry , Temple University , 1901 N. 13th Street , Philadelphia , Pennsylvania 19122 , United States
| | - Yue Zhao
- Department of Chemistry , Temple University , 1901 N. 13th Street , Philadelphia , Pennsylvania 19122 , United States
| | - Si Zhang
- Department of Chemistry , Temple University , 1901 N. 13th Street , Philadelphia , Pennsylvania 19122 , United States
| | - Anisa Eshraghi
- Department of Chemistry , Temple University , 1901 N. 13th Street , Philadelphia , Pennsylvania 19122 , United States
| | - Zakey Yusuf Buuh
- Department of Chemistry , Temple University , 1901 N. 13th Street , Philadelphia , Pennsylvania 19122 , United States
| | - Jeffrey C McGuth
- Department of Chemistry , Temple University , 1901 N. 13th Street , Philadelphia , Pennsylvania 19122 , United States
| | - Yifu Guan
- Department of Chemistry , Temple University , 1901 N. 13th Street , Philadelphia , Pennsylvania 19122 , United States
| | - Jonathan W Engle
- Departments of Radiology and Medical Physics , University of Wisconsin-Madison , Madison , Wisconsin 53705 , United States
| | - Sarah J Bartlett
- Department of Chemistry , Temple University , 1901 N. 13th Street , Philadelphia , Pennsylvania 19122 , United States
| | - Vincent A Voelz
- Department of Chemistry , Temple University , 1901 N. 13th Street , Philadelphia , Pennsylvania 19122 , United States
| | - Weibo Cai
- Departments of Radiology and Medical Physics , University of Wisconsin-Madison , Madison , Wisconsin 53705 , United States
| | - Rongsheng E Wang
- Department of Chemistry , Temple University , 1901 N. 13th Street , Philadelphia , Pennsylvania 19122 , United States
| |
Collapse
|
63
|
FcRn-Dependent Transcytosis of Monoclonal Antibody in Human Nasal Epithelial Cells In Vitro: A Prerequisite for a New Delivery Route for Therapy? Int J Mol Sci 2019; 20:ijms20061379. [PMID: 30893823 PMCID: PMC6470570 DOI: 10.3390/ijms20061379] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2019] [Revised: 03/11/2019] [Accepted: 03/12/2019] [Indexed: 12/27/2022] Open
Abstract
Monoclonal antibodies (mAbs) are promising therapies to treat airway chronic inflammatory disease (asthma or nasal polyps). To date, no study has specifically assessed, in vitro, the potential function of neonatal Fc receptor (FcRn) in IgG transcytosis through the human nasal airway epithelium. The objective of this study was to report the in vitro expression and function of FcRn in nasal human epithelium. FcRn expression was studied in an air–liquid interface (ALI) primary culture model of human nasal epithelial cells (HNEC) from polyps. FcRn expression was characterized by quantitative RT-PCR, western blot, and immunolabeling. The ability of HNECs to support mAb transcytosis via FcRn was assessed by transcytosis assay. This study demonstrates the expression of FcRn mRNA and protein in HNEC. We report a high expression of FcRn in the cytosol of ciliated, mucus, and basal cells by immunohistochemistry with a higher level of FcRn proteins in differentiated HNEC. We also proved in vitro transepithelial delivery of an IgG1 therapeutic mAb with a dose–response curve. This is the first time that FcRn expression and mAb transcytosis has been shown in a model of human nasal respiratory epithelium in vitro. This study is a prerequisite for FcRn-dependent nasal administration of mAbs.
Collapse
|
64
|
Alves NJ. Antibody conjugation and formulation. Antib Ther 2019; 2:33-39. [PMID: 33928219 PMCID: PMC7990145 DOI: 10.1093/abt/tbz002] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2018] [Revised: 01/31/2019] [Accepted: 02/08/2019] [Indexed: 11/14/2022] Open
Abstract
In an era where ultra-high antibody concentrations, high viscosities, low volumes, auto-injectors and long storage requirements are already complex problems with the current unconjugated monoclonal antibodies on the market, the formulation demands for antibody-drug conjugates (ADCs) are significant. Antibodies have historically been administered at relatively low concentrations through intravenous (IV) infusion due to their large size and the inability to formulate for oral delivery. Due to the high demands associated with IV infusion and the development of novel antibody targets and unique antibody conjugates, more accessible routes of administration such as intramuscular and subcutaneous are being explored. This review will summarize various site-specific and non-site-specific antibody conjugation techniques in the context of ADCs and the demands of formulation for high concentration clinical implementation.
Collapse
Affiliation(s)
- Nathan J Alves
- Department of Emergency Medicine, Indiana University School of Medicine, Indianapolis, IN, USA
| |
Collapse
|
65
|
Love EA, Sattikar A, Cook H, Gillen K, Large JM, Patel S, Matthews D, Merritt A. Developing an Antibody-Drug Conjugate Approach to Selective Inhibition of an Extracellular Protein. Chembiochem 2019; 20:754-758. [PMID: 30507063 PMCID: PMC6582441 DOI: 10.1002/cbic.201800623] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2018] [Indexed: 01/20/2023]
Abstract
Antibody–drug conjugates (ADCs) are a growing class of therapeutics that harness the specificity of antibodies and the cell‐killing potency of small‐molecule drugs. Beyond cytotoxics, there are few examples of the application of an ADC approach to difficult drug discovery targets. Here, we present the initial development of a non‐internalising ADC, with a view to selectively inhibiting an extracellular protein. Employing the wellinvestigated matrix metalloproteinase‐9 (MMP‐9) as our model, we adapted a broad‐spectrum, nonselective MMP inhibitor for conjugation and linked this to a MMP‐9‐targeting antibody. The resulting ADC fully inhibits MMP‐9, and ELISA results suggest antibody targeting can direct a nonselective inhibitor.
Collapse
Affiliation(s)
- Elizabeth A Love
- LifeArc, Accelerator Building, Open Innovation Campus, Stevenage, SG1 2FX, UK
| | - Afrah Sattikar
- LifeArc, Accelerator Building, Open Innovation Campus, Stevenage, SG1 2FX, UK
| | - Hannah Cook
- LifeArc, Accelerator Building, Open Innovation Campus, Stevenage, SG1 2FX, UK
| | - Kevin Gillen
- LifeArc, Accelerator Building, Open Innovation Campus, Stevenage, SG1 2FX, UK
| | - Jonathan M Large
- LifeArc, Accelerator Building, Open Innovation Campus, Stevenage, SG1 2FX, UK
| | - Seema Patel
- LifeArc, Accelerator Building, Open Innovation Campus, Stevenage, SG1 2FX, UK
| | - David Matthews
- LifeArc, Accelerator Building, Open Innovation Campus, Stevenage, SG1 2FX, UK
| | - Andy Merritt
- LifeArc, Accelerator Building, Open Innovation Campus, Stevenage, SG1 2FX, UK
| |
Collapse
|
66
|
Tsuchikama K. [Novel Chemical Linkers for Next-generation Antibody-drug Conjugates(ADCs)]. YAKUGAKU ZASSHI 2019; 139:209-219. [PMID: 30713230 DOI: 10.1248/yakushi.18-00169-3] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Antibody-drug conjugates (ADCs), monoclonal antibodies conjugated with highly potent drugs (payloads) through chemical linkers, are an emerging class of therapeutic agents for cancer chemotherapy. Their clinical success has been demonstrated by the 4 ADCs already approved by the U.S. Food and Drug Administration (FDA), and more than 60 promising ADCs now in clinical trials. Further advancement of this novel molecular platform could potentially revolutionize current strategies and regimens for treating cancers. The linker structure and antibody-linker conjugation modality critically contribute to ADC homogeneity, circulation stability, pharmacokinetic profiles, tolerability, and overall treatment efficacy. Despite extensive efforts to improve these parameters, most ADC linkers used to date possess linear structures, and therefore accommodate only single payloads. The clinical potential of branched ADC linkers, enabling the installation of two payload molecules, remains unexplored because of the lack of efficient conjugation methods. In addition, according to a recent report, the stability of enzymatically cleavable linkers in mouse circulation is another crucial factor for the successful evaluation of ADCs in preclinical studies. In this review, I present my research group's effort to develop both branched linkers and efficient conjugation methods for constructing dual-loading ADCs with high homogeneity and enhanced potency. I also present a novel tripeptide ADC linker with enhanced stability in mouse circulation. Multidisciplinary experience, approaches, and collaboration are key to successfully advancing our ADC research programs. I herein describe how my experience in the U.S. has helped to develop and manage complex biomedical research projects in a small academic laboratory setting.
Collapse
Affiliation(s)
- Kyoji Tsuchikama
- Texas Therapeutics Institute, The Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center at Houston
| |
Collapse
|
67
|
Bargh JD, Isidro-Llobet A, Parker JS, Spring DR. Cleavable linkers in antibody–drug conjugates. Chem Soc Rev 2019; 48:4361-4374. [DOI: 10.1039/c8cs00676h] [Citation(s) in RCA: 188] [Impact Index Per Article: 37.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
This tutorial review summarises the advances in the field of cleavable linker technologies for antibody–drug conjugates (ADCs).
Collapse
Affiliation(s)
| | | | - Jeremy S. Parker
- Early Chemical Development
- Pharmaceutical Sciences
- IMED Biotech Unit
- AstraZeneca
- Macclesfield
| | - David R. Spring
- Department of Chemistry
- University of Cambridge
- Cambridge CB2 1EW
- UK
| |
Collapse
|
68
|
Qin SY, Zhang AQ, Zhang XZ. Recent Advances in Targeted Tumor Chemotherapy Based on Smart Nanomedicines. SMALL (WEINHEIM AN DER BERGSTRASSE, GERMANY) 2018; 14:e1802417. [PMID: 30247806 DOI: 10.1002/smll.201802417] [Citation(s) in RCA: 82] [Impact Index Per Article: 13.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/25/2018] [Revised: 08/03/2018] [Indexed: 05/22/2023]
Abstract
Efficacy and safety of chemotherapeutic drugs constitute two major criteria in tumor chemotherapy. Nanomedicines with tumor-targeted properties hold great promise for improving the efficacy and safety. To design targeted nanomedicines, the pathological characteristics of tumors are extensively and deeply excavated. Here, the rationale, principles, and advantages of exploiting these pathological characteristics to develop targeted nanoplatforms for tumor chemotherapy are discussed. Homotypic targeting with the ability of self-recognition to source tumors is reviewed individually. In the meanwhile, the limitations and perspective of these targeted nanomedicines are also discussed.
Collapse
Affiliation(s)
- Si-Yong Qin
- School of Chemistry and Materials Science, South-Central University for Nationalities, Wuhan, 430074, China
- Key Laboratory of Biomedical Polymers of Ministry of Education and Department of Chemistry, Wuhan University, Wuhan, 430072, China
| | - Ai-Qing Zhang
- School of Chemistry and Materials Science, South-Central University for Nationalities, Wuhan, 430074, China
| | - Xian-Zheng Zhang
- Key Laboratory of Biomedical Polymers of Ministry of Education and Department of Chemistry, Wuhan University, Wuhan, 430072, China
| |
Collapse
|
69
|
Oller-Salvia B. Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction. J Vis Exp 2018. [PMID: 30272643 PMCID: PMC6235180 DOI: 10.3791/58066] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023] Open
Abstract
Antibody-drug conjugates (ADCs) used nowadays in clinical practice are mixtures of antibody molecules linked to a varying number of toxins at different positions. Preclinical studies have shown that the therapeutic index of these traditional ADCs can be improved by the site-specific linkage of toxins. However, current approaches to produce homogeneous ADCs have several limitations, such as low protein expression and slow reaction kinetics. In this protocol we describe how to set up an expression system to incorporate a cyclopropene derivative of lysine (CypK) into antibodies using genetic code expansion. This minimal bioorthogonal handle allows rapid conjugation of tetrazine derivatives through an inverse-demand Diels-Alder cycloaddition. The expression system here reported enables the facile production and purification of trastuzumab bearing CypK in each of the heavy chains. We explain how to link the antibody to the toxin monomethyl auristatin E and characterize the immunoconjugate by hydrophobic interaction chromatography and mass spectrometry. Finally, we describe assays to assess the stability in human serum of the dihydropyridazine linkage resulting from the conjugation and to test the selective cytotoxicity of the ADC for breast cancer cells with high levels of HER2 receptor.
Collapse
|
70
|
Cini E, Faltoni V, Petricci E, Taddei M, Salvini L, Giannini G, Vesci L, Milazzo FM, Anastasi AM, Battistuzzi G, De Santis R. Antibody drug conjugates (ADCs) charged with HDAC inhibitor for targeted epigenetic modulation. Chem Sci 2018; 9:6490-6496. [PMID: 30288233 PMCID: PMC6144071 DOI: 10.1039/c7sc05266a] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2017] [Accepted: 06/26/2018] [Indexed: 12/13/2022] Open
Abstract
We describe here two novel antibody-drug conjugates loaded with the HDAC inhibitor ST7612AA1 (IC50 equal to 0.07 μM on NCI-H460 cells), a thiol-based molecule with a moderate toxicity in vivo. Two payloads were prepared using cleavable and non-cleavable linkers. After anchoring to cetuximab through amide bond with lysines, the resulting HDAC inhibitor-antibody conjugates showed ability to recognize EGFR and efficient internalization in tumor cells. Both ADCs induced sensible increment of histones 3 and 4 and alpha-tubulin acetylation. Animal models of human solid tumors showed high anti-tumor efficacy of the conjugates without the toxicity generally observed with traditional ADCs delivering highly potent cytotoxic drugs. These compounds, the first ADCs charged with not highly cytotoxic warheads, are potentially suitable for epigenetic modulation, extending the ADC strategy to the targeted delivery of HDAC inhibitors with many possible therapeutic applications beyond cancer.
Collapse
Affiliation(s)
- Elena Cini
- Lead Discovery Siena srl , Via Fiorentina 1 , 53100 Siena , Italy
| | - Valentina Faltoni
- Dipartimento di Biotecnologie , Chimica e Farmacia , Università degli Studi di Siena , Via A. Moro 2 , 53100 Siena , Italy .
| | - Elena Petricci
- Dipartimento di Biotecnologie , Chimica e Farmacia , Università degli Studi di Siena , Via A. Moro 2 , 53100 Siena , Italy .
| | - Maurizio Taddei
- Dipartimento di Biotecnologie , Chimica e Farmacia , Università degli Studi di Siena , Via A. Moro 2 , 53100 Siena , Italy .
| | - Laura Salvini
- Fondazione Toscana Life Sciences , Via Fiorentina 1 , 53100 Siena , Italy
| | - Giuseppe Giannini
- R&D Alfasigma S.p.A. , Via Pontina, Km. 30.400 , 00071 Pomezia , Roma , Italy .
| | - Loredana Vesci
- R&D Alfasigma S.p.A. , Via Pontina, Km. 30.400 , 00071 Pomezia , Roma , Italy .
| | | | - Anna Maria Anastasi
- R&D Alfasigma S.p.A. , Via Pontina, Km. 30.400 , 00071 Pomezia , Roma , Italy .
| | | | - Rita De Santis
- R&D Alfasigma S.p.A. , Via Pontina, Km. 30.400 , 00071 Pomezia , Roma , Italy .
| |
Collapse
|
71
|
Karpov AS, Abrams T, Clark S, Raikar A, D’Alessio JA, Dillon MP, Gesner TG, Jones D, Lacaud M, Mallet W, Martyniuk P, Meredith E, Mohseni M, Nieto-Oberhuber CM, Palacios D, Perruccio F, Piizzi G, Zurini M, Bialucha CU. Nicotinamide Phosphoribosyltransferase Inhibitor as a Novel Payload for Antibody-Drug Conjugates. ACS Med Chem Lett 2018; 9:838-842. [PMID: 30128077 PMCID: PMC6088352 DOI: 10.1021/acsmedchemlett.8b00254] [Citation(s) in RCA: 25] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2018] [Accepted: 06/28/2018] [Indexed: 11/28/2022] Open
Abstract
Antibody-drug conjugates (ADCs) are a novel modality that allows targeted delivery of potent therapeutic agents to the desired site. Herein we report our discovery of NAMPT inhibitors as a novel nonantimitotic payload for ADCs. The resulting anti-c-Kit conjugates (ADC-3 and ADC-4) demonstrated in vivo efficacy in the c-Kit positive gastrointestinal stromal tumor GIST-T1 xenograft model in a target-dependent manner.
Collapse
Affiliation(s)
- Alexei S. Karpov
- Novartis Institutes for BioMedical Research, CH-4056 Basel, Switzerland
| | - Tinya Abrams
- Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States
| | - Suzanna Clark
- Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States
| | - Ankita Raikar
- Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States
| | - Joseph A. D’Alessio
- Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States
| | - Michael P. Dillon
- Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States
| | - Thomas G. Gesner
- Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States
| | - Darryl Jones
- Novartis Institutes for BioMedical Research, CH-4056 Basel, Switzerland
| | - Marion Lacaud
- Novartis Institutes for BioMedical Research, CH-4056 Basel, Switzerland
| | - William Mallet
- Novartis Institutes for BioMedical Research, 5300 Chiron Way, Emeryville, California 94608, United States
| | - Piotr Martyniuk
- Novartis Institutes for BioMedical Research, CH-4056 Basel, Switzerland
| | - Erik Meredith
- Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States
| | - Morvarid Mohseni
- Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States
| | | | - Daniel Palacios
- Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States
| | | | - Grazia Piizzi
- Novartis Institutes for BioMedical Research, CH-4056 Basel, Switzerland
| | - Mauro Zurini
- Novartis Institutes for BioMedical Research, CH-4056 Basel, Switzerland
| | - Carl Uli Bialucha
- Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States
| |
Collapse
|
72
|
Beaumont M, Tomazela D, Hodges D, Ermakov G, Hsieh E, Figueroa I, So OY, Song Y, Ma H, Antonenko S, Mengesha W, Zhang YW, Zhang S, Hseih S, Ayanoglu G, Du X, Rimmer E, Judo M, Vives F, Yearley JH, Moon C, Manibusan A, Knudsen N, Beck A, Bresson D, Gately D, Neupane D, Escandón E. Antibody-drug conjugates: integrated bioanalytical and biodisposition assessments in lead optimization and selection. AAPS OPEN 2018. [DOI: 10.1186/s41120-018-0026-0] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
73
|
Marmelstein AM, Morgan JAM, Penkert M, Rogerson DT, Chin JW, Krause E, Fiedler D. Pyrophosphorylation via selective phosphoprotein derivatization. Chem Sci 2018; 9:5929-5936. [PMID: 30079207 PMCID: PMC6050540 DOI: 10.1039/c8sc01233d] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2018] [Accepted: 06/08/2018] [Indexed: 01/13/2023] Open
Abstract
An important step in elucidating the function of protein post-translational modifications (PTMs) is gaining access to site-specifically modified, homogeneous samples for biochemical characterization. Protein pyrophosphorylation is a poorly characterized PTM, and here a chemical approach to obtain pyrophosphoproteins is reported. Photo-labile phosphorimidazolide reagents were developed for selective pyrophosphorylation, affinity-capture, and release of pyrophosphoproteins. Kinetic analysis of the reaction revealed rate constants between 9.2 × 10-3 to 0.58 M-1 s-1, as well as a striking proclivity of the phosphorimidazolides to preferentially react with phosphate monoesters over other nucleophilic side chains. Besides enabling the characterization of pyrophosphorylation on protein function, this work highlights the utility of phosphoryl groups as handles for selective protein modification for a variety of applications, such as phosphoprotein bioconjugation and enrichment.
Collapse
Affiliation(s)
- Alan M Marmelstein
- Leibniz-Forschungsinstitut für Molekulare Pharmakologie , Robert-Rössle Str. 10 , 13125 Berlin , Germany .
- Department of Chemistry , Princeton University , Washington Road , Princeton , New Jersey 08544 , USA
| | - Jeremy A M Morgan
- Leibniz-Forschungsinstitut für Molekulare Pharmakologie , Robert-Rössle Str. 10 , 13125 Berlin , Germany .
| | - Martin Penkert
- Leibniz-Forschungsinstitut für Molekulare Pharmakologie , Robert-Rössle Str. 10 , 13125 Berlin , Germany .
- Institut für Chemie , Humboldt Universität zu Berlin , Brook-Taylor-Str. 2 , 12489 Berlin , Germany
| | - Daniel T Rogerson
- Medical Research Council Laboratory of Molecular Biology , Francis Crick Avenue , Cambridge , UK
| | - Jason W Chin
- Medical Research Council Laboratory of Molecular Biology , Francis Crick Avenue , Cambridge , UK
| | - Eberhard Krause
- Leibniz-Forschungsinstitut für Molekulare Pharmakologie , Robert-Rössle Str. 10 , 13125 Berlin , Germany .
| | - Dorothea Fiedler
- Leibniz-Forschungsinstitut für Molekulare Pharmakologie , Robert-Rössle Str. 10 , 13125 Berlin , Germany .
- Institut für Chemie , Humboldt Universität zu Berlin , Brook-Taylor-Str. 2 , 12489 Berlin , Germany
| |
Collapse
|
74
|
Anami Y, Yamazaki CM, Xiong W, Gui X, Zhang N, An Z, Tsuchikama K. Glutamic acid-valine-citrulline linkers ensure stability and efficacy of antibody-drug conjugates in mice. Nat Commun 2018; 9:2512. [PMID: 29955061 PMCID: PMC6023893 DOI: 10.1038/s41467-018-04982-3] [Citation(s) in RCA: 105] [Impact Index Per Article: 17.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2018] [Accepted: 06/05/2018] [Indexed: 11/24/2022] Open
Abstract
Valine-citrulline linkers are commonly used as enzymatically cleavable linkers for antibody-drug conjugates. While stable in human plasma, these linkers are unstable in mouse plasma due to susceptibility to an extracellular carboxylesterase. This instability often triggers premature release of drugs in mouse circulation, presenting a molecular design challenge. Here, we report that an antibody-drug conjugate with glutamic acid-valine-citrulline linkers is responsive to enzymatic drug release but undergoes almost no premature cleavage in mice. We demonstrate that this construct exhibits greater treatment efficacy in mouse tumor models than does a valine-citrulline-based variant. Notably, our antibody-drug conjugate contains long spacers facilitating the protease access to the linker moiety, indicating that our linker assures high in vivo stability despite a high degree of exposure. This technology could add flexibility to antibody-drug conjugate design and help minimize failure rates in pre-clinical studies caused by linker instability.
Collapse
Affiliation(s)
- Yasuaki Anami
- Texas Therapeutics Institute, The Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center at Houston, 1881 East Road, Houston, TX, 77054, USA
| | - Chisato M Yamazaki
- Texas Therapeutics Institute, The Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center at Houston, 1881 East Road, Houston, TX, 77054, USA
| | - Wei Xiong
- Texas Therapeutics Institute, The Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center at Houston, 1881 East Road, Houston, TX, 77054, USA
| | - Xun Gui
- Texas Therapeutics Institute, The Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center at Houston, 1881 East Road, Houston, TX, 77054, USA
| | - Ningyan Zhang
- Texas Therapeutics Institute, The Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center at Houston, 1881 East Road, Houston, TX, 77054, USA
| | - Zhiqiang An
- Texas Therapeutics Institute, The Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center at Houston, 1881 East Road, Houston, TX, 77054, USA
| | - Kyoji Tsuchikama
- Texas Therapeutics Institute, The Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center at Houston, 1881 East Road, Houston, TX, 77054, USA.
| |
Collapse
|
75
|
Zheng Y, Ji X, Yu B, Ji K, Gallo D, Csizmadia E, Zhu M, Choudhury MR, De La Cruz LKC, Chittavong V, Pan Z, Yuan Z, Otterbein LE, Wang B. Enrichment-triggered prodrug activation demonstrated through mitochondria-targeted delivery of doxorubicin and carbon monoxide. Nat Chem 2018; 10:787-794. [PMID: 29760413 PMCID: PMC6235738 DOI: 10.1038/s41557-018-0055-2] [Citation(s) in RCA: 190] [Impact Index Per Article: 31.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2017] [Accepted: 03/29/2018] [Indexed: 02/08/2023]
Abstract
Controlled activation is a critical component in prodrug development. Herein we report a concentration-sensitive platform approach for bioorthogonal prodrug activation by taking advantage of reaction kinetics. Using two “click and release” systems, we demonstrate enrichment and prodrug activation specifically in mitochondria to demonstrate the principle of this approach. In both cases, the payload (doxorubicin or carbon monoxide) was released inside the mitochondrial matrix upon the enrichment-initiated click reaction. Furthermore, mitochondria-targeted delivery yielded substantial augmentation of functional biological and therapeutic effects in vitro and in vivo, as compared to controls that did not result in enrichment. This method is thus a platform for targeted drug delivery amenable to conjugation with a variety of molecules and not limited to cell-surface delivery. Taken together, these two click and release pairs clearly demonstrate the concept of enrichment-triggered drug release and critical feasibility of treating clinically relevant diseases such as acute liver injury and cancer.
Collapse
Affiliation(s)
- Yueqin Zheng
- Department of Chemistry and Center for Diagnostics and Therapeutics, Georgia State University, Atlanta, GA, USA.,Center for Diagnostics and Therapeutics, Georgia State University, Atlanta, GA, USA
| | - Xingyue Ji
- Department of Chemistry and Center for Diagnostics and Therapeutics, Georgia State University, Atlanta, GA, USA.,Center for Diagnostics and Therapeutics, Georgia State University, Atlanta, GA, USA
| | - Bingchen Yu
- Department of Chemistry and Center for Diagnostics and Therapeutics, Georgia State University, Atlanta, GA, USA.,Center for Diagnostics and Therapeutics, Georgia State University, Atlanta, GA, USA
| | - Kaili Ji
- Department of Chemistry and Center for Diagnostics and Therapeutics, Georgia State University, Atlanta, GA, USA.,Center for Diagnostics and Therapeutics, Georgia State University, Atlanta, GA, USA
| | - David Gallo
- Harvard Medical School, Department of Surgery, Beth Israel Deaconess Medical Center, Boston, MA, USA
| | - Eva Csizmadia
- Harvard Medical School, Department of Surgery, Beth Israel Deaconess Medical Center, Boston, MA, USA
| | - Mengyuan Zhu
- Department of Chemistry and Center for Diagnostics and Therapeutics, Georgia State University, Atlanta, GA, USA.,Center for Diagnostics and Therapeutics, Georgia State University, Atlanta, GA, USA
| | - Manjusha Roy Choudhury
- Department of Chemistry and Center for Diagnostics and Therapeutics, Georgia State University, Atlanta, GA, USA.,Center for Diagnostics and Therapeutics, Georgia State University, Atlanta, GA, USA
| | - Ladie Kimberly C De La Cruz
- Department of Chemistry and Center for Diagnostics and Therapeutics, Georgia State University, Atlanta, GA, USA.,Center for Diagnostics and Therapeutics, Georgia State University, Atlanta, GA, USA
| | - Vayou Chittavong
- Department of Chemistry and Center for Diagnostics and Therapeutics, Georgia State University, Atlanta, GA, USA.,Center for Diagnostics and Therapeutics, Georgia State University, Atlanta, GA, USA
| | - Zhixiang Pan
- Department of Chemistry and Center for Diagnostics and Therapeutics, Georgia State University, Atlanta, GA, USA.,Center for Diagnostics and Therapeutics, Georgia State University, Atlanta, GA, USA
| | - Zhengnan Yuan
- Department of Chemistry and Center for Diagnostics and Therapeutics, Georgia State University, Atlanta, GA, USA.,Center for Diagnostics and Therapeutics, Georgia State University, Atlanta, GA, USA
| | - Leo E Otterbein
- Harvard Medical School, Department of Surgery, Beth Israel Deaconess Medical Center, Boston, MA, USA.
| | - Binghe Wang
- Department of Chemistry and Center for Diagnostics and Therapeutics, Georgia State University, Atlanta, GA, USA. .,Center for Diagnostics and Therapeutics, Georgia State University, Atlanta, GA, USA.
| |
Collapse
|
76
|
Anderson BA, Krishnamurthy R. Heterogeneous Pyrophosphate-Linked DNA-Oligonucleotides: Aversion to DNA but Affinity for RNA. Chemistry 2018. [PMID: 29532524 DOI: 10.1002/chem.201800538] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
Abstract
Pyrophosphate linkages are important in extant biology and are hypothesized to have played a role in prebiotic chemistry and in the origination of oligonucleotides. Inspired by pyrophosphate as backbones of primordial oligomers, DNA oligomers with varying amounts of pyrophosphate inserts (ppDNA) were synthesized and investigated for their base-pairing properties. As expected, pyrophosphate inserts into the backbone compromised the thermal stability of ppDNA-DNA duplexes. In contrast, the ppDNA-RNA duplex exhibited, remarkably, duplex stability, even with accumulation of pyrophosphate linkages. This seems to be a consequence of an increase in the diameter of the double-helix with eight-bond-repeat units, and higher inclination of the base-pair axis with respect to the backbone in RNA (A-form), compared with that in DNA (B-form). These results suggest that pyrophosphate-linked oligonucleotides could harbor functional capabilities with implications for their roles in the origins of life and chemical biology.
Collapse
Affiliation(s)
- Brooke A Anderson
- Department of Chemistry, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA, 92037, USA
| | - Ramanarayanan Krishnamurthy
- Department of Chemistry, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA, 92037, USA
| |
Collapse
|
77
|
Dragovich PS, Blake RA, Chen C, Chen J, Chuh J, den Besten W, Fan F, Fourie A, Hartman SJ, He C, He J, Ingalla ER, Kozak KR, Leong SR, Lu J, Ma Y, Meng L, Nannini M, Oeh J, Ohri R, Lewis Phillips G, Pillow TH, Rowntree RK, Sampath D, Vandlen R, Vollmar B, Wai J, Wertz IE, Xu K, Xu Z, Zhang D. Conjugation of Indoles to Antibodies through a Novel Self-Immolating Linker. Chemistry 2018; 24:4830-4834. [DOI: 10.1002/chem.201800859] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2018] [Indexed: 01/05/2023]
Affiliation(s)
| | | | - Chunjiao Chen
- WuXi Biologics; 288 Fute Zhong Road, Waigaoqiao Free Trade Zone Shanghai 200131 P. R. China
| | - Jinhua Chen
- WuXi Apptec; 288 Fute Zhong Road, Waigaoqiao Free Trade Zone Shanghai 200131 P. R. China
| | - Josefa Chuh
- Genentech Inc.; 1 DNA Way South San Francisco CA 94080 USA
| | | | - Fang Fan
- WuXi Apptec; 288 Fute Zhong Road, Waigaoqiao Free Trade Zone Shanghai 200131 P. R. China
| | - Aimee Fourie
- Genentech Inc.; 1 DNA Way South San Francisco CA 94080 USA
| | | | - Changrong He
- WuXi Apptec; 288 Fute Zhong Road, Waigaoqiao Free Trade Zone Shanghai 200131 P. R. China
| | - Jintang He
- Genentech Inc.; 1 DNA Way South San Francisco CA 94080 USA
| | | | | | | | - Jiawei Lu
- WuXi Biologics; 288 Fute Zhong Road, Waigaoqiao Free Trade Zone Shanghai 200131 P. R. China
| | - Yong Ma
- Genentech Inc.; 1 DNA Way South San Francisco CA 94080 USA
| | - Lingyao Meng
- Genentech Inc.; 1 DNA Way South San Francisco CA 94080 USA
| | | | - Jason Oeh
- Genentech Inc.; 1 DNA Way South San Francisco CA 94080 USA
| | - Rachana Ohri
- Genentech Inc.; 1 DNA Way South San Francisco CA 94080 USA
| | | | | | | | - Deepak Sampath
- Genentech Inc.; 1 DNA Way South San Francisco CA 94080 USA
| | | | | | - John Wai
- WuXi Apptec; 288 Fute Zhong Road, Waigaoqiao Free Trade Zone Shanghai 200131 P. R. China
| | | | - Keyang Xu
- Genentech Inc.; 1 DNA Way South San Francisco CA 94080 USA
| | - Zijin Xu
- WuXi Apptec; 288 Fute Zhong Road, Waigaoqiao Free Trade Zone Shanghai 200131 P. R. China
| | - Donglu Zhang
- Genentech Inc.; 1 DNA Way South San Francisco CA 94080 USA
| |
Collapse
|
78
|
A Polar Sulfamide Spacer Significantly Enhances the Manufacturability, Stability, and Therapeutic Index of Antibody-Drug Conjugates. Antibodies (Basel) 2018; 7:antib7010012. [PMID: 31544864 PMCID: PMC6698870 DOI: 10.3390/antib7010012] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2018] [Revised: 02/08/2018] [Accepted: 02/17/2018] [Indexed: 11/17/2022] Open
Abstract
Despite tremendous efforts in the field of targeted cancer therapy with antibody–drug conjugates (ADCs), attrition rates have been high. Historically, the priority in ADC development has been the selection of target, antibody, and toxin, with little focus on the nature of the linker. We show here that a short and polar sulfamide spacer (HydraSpace™, Oss, The Netherlands) positively impacts ADC properties in various ways: (a) efficiency of conjugation; (b) stability; and (c) therapeutic index. Different ADC formats are explored in terms of drug-to-antibody ratios (DAR2, DAR4) and we describe the generation of a DAR4 ADC by site-specific attachment of a bivalent linker–payload construct to a single conjugation site in the antibody. A head-to-head comparison of HydraSpace™-containing DAR4 ADCs to marketed drugs, derived from the same antibody and toxic payload components, indicated a significant improvement in both the efficacy and safety of several vivo models, corroborated by in-depth pharmacokinetic analysis. Taken together, HydraSpace™ technology based on a polar sulfamide spacer provides significant improvement in manufacturability, stability, and ADC design, and is a powerful platform to enable next-generation ADCs with enhanced therapeutic index.
Collapse
|
79
|
Yokosaka S, Izawa A, Sakai C, Sakurada E, Morita Y, Nishio Y. Synthesis and evaluation of novel dolastatin 10 derivatives for versatile conjugations. Bioorg Med Chem 2018; 26:1643-1652. [PMID: 29454703 DOI: 10.1016/j.bmc.2018.02.011] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/27/2017] [Revised: 02/09/2018] [Accepted: 02/10/2018] [Indexed: 11/15/2022]
Abstract
Dolastatin 10 (1) is a highly potent cytotoxic microtubule inhibitor (cytotoxicity IC50 < 5.0 nM) and several of its analogs have recently been used as payloads in antibody drug conjugates. Herein, we describe the design and synthesis of a series of novel dolastatin 10 analogs useful as payloads for conjugated drugs. We explored analogs containing functional groups at the thiazole moiety at the C-terminal of dolastatin 10. The functional groups included amines, alcohols, and thiols, which are representative structures used in known conjugated drugs. These novel analogs showed excellent potency in a tumor cell proliferation assay, and thus this series of dolastatin 10 analogs is suitable as versatile payloads in conjugated drugs. Insights into the structure-activity relationships of the analogs are also discussed.
Collapse
Affiliation(s)
- Shinya Yokosaka
- Toray Industries Inc., Pharmaceutical Research Laboratories, 6-10-1 Tebiro, Kamakura, Kanagawa 248-8555, Japan
| | - Akiko Izawa
- Toray Industries Inc., Pharmaceutical Research Laboratories, 6-10-1 Tebiro, Kamakura, Kanagawa 248-8555, Japan
| | - Chizuka Sakai
- Toray Industries Inc., Pharmaceutical Research Laboratories, 6-10-1 Tebiro, Kamakura, Kanagawa 248-8555, Japan
| | - Eri Sakurada
- Toray Industries Inc., Pharmaceutical Research Laboratories, 6-10-1 Tebiro, Kamakura, Kanagawa 248-8555, Japan
| | - Yasuhiro Morita
- Toray Industries Inc., Pharmaceutical Research Laboratories, 6-10-1 Tebiro, Kamakura, Kanagawa 248-8555, Japan
| | - Yukihiro Nishio
- Toray Industries Inc., Pharmaceutical Research Laboratories, 6-10-1 Tebiro, Kamakura, Kanagawa 248-8555, Japan.
| |
Collapse
|
80
|
Abstract
The antibody-drug conjugate (ADC) field is in a transitional period. Older approaches to conjugate composition and dosing regimens still dominate the ADC clinical pipeline, but preclinical work is driving a rapid evolution in how we strategize to improve efficacy and reduce toxicity towards better therapeutic outcomes. These advances are largely based upon a body of investigational studies that together offer a deeper understanding of the absorption, distribution, metabolism, and excretion (ADME) and drug metabolism and pharmacokinetics (DMPK) fates of both the intact conjugate and its small-molecule component. Knowing where the drug goes and how it is processed allows mechanistic connections to be drawn with commonly observed clinical toxicities. The field is also starting to consider ADC interactions with the immune system and potential synergistic therapeutic opportunities therein. In an indication of future directions for the field, antibody conjugates bearing non-cytotoxic small-molecule payloads are being developed to reduce side effects associated with treatment of chronic diseases. ADCs are not a magic bullet to cure disease. However, they will increasingly become valuable therapeutic tools to improve patient outcomes across a variety of indications.
Collapse
Affiliation(s)
- Penelope M Drake
- Catalent Biologics, 5703 Hollis Street, Emeryville, CA, 94608, USA
| | - David Rabuka
- Catalent Biologics, 5703 Hollis Street, Emeryville, CA, 94608, USA.
| |
Collapse
|
81
|
Dutta AK, Captain I, Jessen HJ. New Synthetic Methods for Phosphate Labeling. Top Curr Chem (Cham) 2017; 375:51. [DOI: 10.1007/s41061-017-0135-6] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2016] [Accepted: 03/27/2017] [Indexed: 12/12/2022]
|
82
|
Pillow TH, Schutten M, Yu SF, Ohri R, Sadowsky J, Poon KA, Solis W, Zhong F, Del Rosario G, Go MAT, Lau J, Yee S, He J, Liu L, Ng C, Xu K, Leipold DD, Kamath AV, Zhang D, Masterson L, Gregson SJ, Howard PW, Fang F, Chen J, Gunzner-Toste J, Kozak KK, Spencer S, Polakis P, Polson AG, Flygare JA, Junutula JR. Modulating Therapeutic Activity and Toxicity of Pyrrolobenzodiazepine Antibody-Drug Conjugates with Self-Immolative Disulfide Linkers. Mol Cancer Ther 2017; 16:871-878. [PMID: 28223423 DOI: 10.1158/1535-7163.mct-16-0641] [Citation(s) in RCA: 52] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2016] [Revised: 10/19/2016] [Accepted: 01/24/2017] [Indexed: 11/16/2022]
Abstract
A novel disulfide linker was designed to enable a direct connection between cytotoxic pyrrolobenzodiazepine (PBD) drugs and the cysteine on a targeting antibody for use in antibody-drug conjugates (ADCs). ADCs composed of a cysteine-engineered antibody were armed with a PBD using a self-immolative disulfide linker. Both the chemical linker and the antibody site were optimized for this new bioconjugation strategy to provide a highly stable and efficacious ADC. This novel disulfide ADC was compared with a conjugate containing the same PBD drug, but attached to the antibody via a peptide linker. Both ADCs had similar efficacy in mice bearing human tumor xenografts. Safety studies in rats revealed that the disulfide-linked ADC had a higher MTD than the peptide-linked ADC. Overall, these data suggest that the novel self-immolative disulfide linker represents a valuable way to construct ADCs with equivalent efficacy and improved safety. Mol Cancer Ther; 16(5); 871-8. ©2017 AACR.
Collapse
Affiliation(s)
| | | | - Shang-Fan Yu
- Genentech, Inc., South San Francisco, California
| | - Rachana Ohri
- Genentech, Inc., South San Francisco, California
| | | | | | - Willy Solis
- Genentech, Inc., South San Francisco, California
| | - Fiona Zhong
- Genentech, Inc., South San Francisco, California
| | | | | | - Jeffrey Lau
- Genentech, Inc., South San Francisco, California
| | - Sharon Yee
- Genentech, Inc., South San Francisco, California
| | - Jintang He
- Genentech, Inc., South San Francisco, California
| | - Luna Liu
- Genentech, Inc., South San Francisco, California
| | - Carl Ng
- Genentech, Inc., South San Francisco, California
| | - Keyang Xu
- Genentech, Inc., South San Francisco, California
| | | | | | - Donglu Zhang
- Genentech, Inc., South San Francisco, California
| | - Luke Masterson
- Spirogen Ltd., QMB Innovation Centre, London, United Kingdom
| | | | - Philip W Howard
- Spirogen Ltd., QMB Innovation Centre, London, United Kingdom
| | - Fan Fang
- WuXi AppTec Co., Ltd., Shanghai, P.R. China
| | | | | | | | | | - Paul Polakis
- Genentech, Inc., South San Francisco, California
| | | | | | | |
Collapse
|
83
|
Novel linkers and connections for antibody-drug conjugates to treat cancer and infectious disease. Pharm Pat Anal 2017; 6:25-33. [PMID: 28155578 DOI: 10.4155/ppa-2016-0032] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Antibody-drug conjugates (ADCs) are an exciting therapeutic, combining the extreme potency of a small molecule cytotoxic drug with the exquisite selectivity of a monoclonal antibody. Despite the promising concept and many decades of research and clinical experiments, only two ADCs are approved for human use. Among the lessons learned, have been the need for highly stable and potentially releasable linkers and the empirical nature of therapeutic index supporting the testing of many diverse cytotoxics, many requiring new linker connections for the drug's available functional groups. This article will focus on our efforts at Genentech to develop a new disulfide linker as well as our discovery of a novel quaternary ammonium salt linker connection and the application to ADCs for cancer and infectious disease.
Collapse
|
84
|
Wang YJ, Li YY, Liu XY, Lu XL, Cao X, Jiao BH. Marine Antibody-Drug Conjugates: Design Strategies and Research Progress. Mar Drugs 2017; 15:E18. [PMID: 28098746 PMCID: PMC5295238 DOI: 10.3390/md15010018] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2016] [Revised: 12/30/2016] [Accepted: 01/04/2017] [Indexed: 01/22/2023] Open
Abstract
Antibody-drug conjugates (ADCs), constructed with monoclonal antibodies (mAbs), linkers, and natural cytotoxins, are innovative drugs developed for oncotherapy. Owing to the distinctive advantages of both chemotherapy drugs and antibody drugs, ADCs have obtained enormous success during the past several years. The development of highly specific antibodies, novel marine toxins' applications, and innovative linker technologies all accelerate the rapid R&D of ADCs. Meanwhile, some challenges remain to be solved for future ADCs. For instance, varieties of site-specific conjugation have been proposed for solving the inhomogeneity of DARs (Drug Antibody Ratios). In this review, the usages of various natural toxins, especially marine cytotoxins, and the development strategies for ADCs in the past decade are summarized. Representative ADCs with marine cytotoxins in the pipeline are introduced and characterized with their new features, while perspective comments for future ADCs are proposed.
Collapse
Affiliation(s)
- Yu-Jie Wang
- Department of Biochemistry and Molecular Biology, Second Military Medical University, Shanghai 200433, China.
- Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing 210009, China.
| | - Yu-Yan Li
- Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing 210009, China.
| | - Xiao-Yu Liu
- Department of Biochemistry and Molecular Biology, Second Military Medical University, Shanghai 200433, China.
| | - Xiao-Ling Lu
- Department of Biochemistry and Molecular Biology, Second Military Medical University, Shanghai 200433, China.
| | - Xin Cao
- Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai 200032, China.
| | - Bing-Hua Jiao
- Department of Biochemistry and Molecular Biology, Second Military Medical University, Shanghai 200433, China.
| |
Collapse
|
85
|
Nunes JPM, Vassileva V, Robinson E, Morais M, Smith MEB, Pedley RB, Caddick S, Baker JR, Chudasama V. Use of a next generation maleimide in combination with THIOMAB™ antibody technology delivers a highly stable, potent and near homogeneous THIOMAB™ antibody-drug conjugate (TDC). RSC Adv 2017. [DOI: 10.1039/c7ra04606e] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
Conjugation of next generation maleimides to engineered cysteines in a THIOMAB™ antibody delivers a highly stable and potent THIOMAB™ antibody-drug conjugate.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | - James R. Baker
- Department of Chemistry
- University College London
- London
- UK
| | - Vijay Chudasama
- Department of Chemistry
- University College London
- London
- UK
- Research Institute for Medicines (iMed.ULisboa)
| |
Collapse
|
86
|
Robinson E, Nunes JPM, Vassileva V, Maruani A, Nogueira JCF, Smith MEB, Pedley RB, Caddick S, Baker JR, Chudasama V. Pyridazinediones deliver potent, stable, targeted and efficacious antibody–drug conjugates (ADCs) with a controlled loading of 4 drugs per antibody. RSC Adv 2017. [DOI: 10.1039/c7ra00788d] [Citation(s) in RCA: 50] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
Delivering potent, stable, targeted and in vivo efficacious antibody–drug conjugates (ADCs) using pyridazinedione functional disulfide re-bridging reagents.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | - James R. Baker
- Department of Chemistry
- University College London
- London
- UK
| | | |
Collapse
|
87
|
Self-assembled structures and excellent surface properties of a novel anionic phosphate diester surfactant derived from natural rosin acids. J Colloid Interface Sci 2017; 486:67-74. [DOI: 10.1016/j.jcis.2016.09.061] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2016] [Revised: 09/22/2016] [Accepted: 09/26/2016] [Indexed: 11/22/2022]
|
88
|
Tsuchikama K, An Z. Antibody-drug conjugates: recent advances in conjugation and linker chemistries. Protein Cell 2016; 9:33-46. [PMID: 27743348 PMCID: PMC5777969 DOI: 10.1007/s13238-016-0323-0] [Citation(s) in RCA: 431] [Impact Index Per Article: 53.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2016] [Accepted: 08/06/2016] [Indexed: 01/11/2023] Open
Abstract
The antibody-drug conjugate (ADC), a humanized or human monoclonal antibody conjugated with highly cytotoxic small molecules (payloads) through chemical linkers, is a novel therapeutic format and has great potential to make a paradigm shift in cancer chemotherapy. This new antibody-based molecular platform enables selective delivery of a potent cytotoxic payload to target cancer cells, resulting in improved efficacy, reduced systemic toxicity, and preferable pharmacokinetics (PK)/pharmacodynamics (PD) and biodistribution compared to traditional chemotherapy. Boosted by the successes of FDA-approved Adcetris® and Kadcyla®, this drug class has been rapidly growing along with about 60 ADCs currently in clinical trials. In this article, we briefly review molecular aspects of each component (the antibody, payload, and linker) of ADCs, and then mainly discuss traditional and new technologies of the conjugation and linker chemistries for successful construction of clinically effective ADCs. Current efforts in the conjugation and linker chemistries will provide greater insights into molecular design and strategies for clinically effective ADCs from medicinal chemistry and pharmacology standpoints. The development of site-specific conjugation methodologies for constructing homogeneous ADCs is an especially promising path to improving ADC design, which will open the way for novel cancer therapeutics.
Collapse
Affiliation(s)
- Kyoji Tsuchikama
- Texas Therapeutics Institute, The Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center at Houston, Houston, TX, 77054, USA.
| | - Zhiqiang An
- Texas Therapeutics Institute, The Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center at Houston, Houston, TX, 77054, USA
| |
Collapse
|
89
|
Kern JC, Dooney D, Zhang R, Liang L, Brandish PE, Cheng M, Feng G, Beck A, Bresson D, Firdos J, Gately D, Knudsen N, Manibusan A, Sun Y, Garbaccio RM. Novel Phosphate Modified Cathepsin B Linkers: Improving Aqueous Solubility and Enhancing Payload Scope of ADCs. Bioconjug Chem 2016; 27:2081-8. [PMID: 27469406 DOI: 10.1021/acs.bioconjchem.6b00337] [Citation(s) in RCA: 52] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
In an effort to examine the utility of antibody-drug conjugates (ADCs) beyond oncology indications, a novel phosphate bridged Cathepsin B sensitive linker was developed to enable the targeted delivery of glucocorticoids. Phosphate bridging of the Cathepsin B sensitive linkers allows for payload attachment at an aliphatic alcohol. As small molecule drug-linkers, these aqueous soluble phosphate containing drug-linkers were found to have robust plasma stability coupled with rapid release of payload in a lysosomal environment. Site-specific ADCs were successfully made between these drug-linkers and an antibody against human CD70, a receptor specifically expressed in immune cells but also found aberrantly expressed in multiple human carcinomas. These ADCs demonstrated in vitro targeted delivery of glucocorticoids to a representative cell line as measured by changes in glucocorticoid receptor (GR) mediated gene mRNA levels. This novel linker expands the scope of potential ADC payloads by allowing an aliphatic alcohol to be a stable, yet cleavable attachment site. This phosphate linker may have broad utility for internalizing ADCs as well as other targeted delivery platforms.
Collapse
Affiliation(s)
| | | | | | - Linda Liang
- Biologics, Merck & Co., Inc. , 901 California Avenue, Palo Alto, California 94304, United States
| | | | | | | | - Andrew Beck
- Ambrx , 10975 North Torrey Pines Road, San Diego, California 92121, United States
| | - Damien Bresson
- Ambrx , 10975 North Torrey Pines Road, San Diego, California 92121, United States
| | - Juhi Firdos
- Ambrx , 10975 North Torrey Pines Road, San Diego, California 92121, United States
| | - Dennis Gately
- Ambrx , 10975 North Torrey Pines Road, San Diego, California 92121, United States
| | - Nick Knudsen
- Ambrx , 10975 North Torrey Pines Road, San Diego, California 92121, United States
| | - Anthony Manibusan
- Ambrx , 10975 North Torrey Pines Road, San Diego, California 92121, United States
| | - Ying Sun
- Ambrx , 10975 North Torrey Pines Road, San Diego, California 92121, United States
| | | |
Collapse
|